Jarkko Ahvonen
Overview
Explore the profile of Jarkko Ahvonen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
58
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Leskela R, Korhonen S, Haavisto I, Nuutinen M, Peltonen E, Herse F, et al.
Acta Oncol
. 2023 Jul;
62(6):587-593.
PMID: 37459504
Aim: The aim of this descriptive study is to analyze the cost for the treatment of NSCLC and SCLC patients (2014-2019) in Finland. The primary objective is to understand recent...
2.
Kuusisalo S, Tikkanen A, Lappi-Blanco E, Vaisanen T, Aija Knuuttila , Tiainen S, et al.
Cancer Med
. 2023 Jun;
12(15):16087-16097.
PMID: 37329173
Background: Anti-PD-(L)1 agents have revolutionized the treatment paradigms of non-small cell lung cancer (NSCLC), while predictive biomarkers are limited. It has been previously shown that systemic inflammation, indicated by elevated...
3.
Ahvonen J, Luukkaala T, Laitinen T, Jukkola A
Acta Oncol
. 2023 May;
62(6):571-578.
PMID: 37257498
Objectives: According to the CONCORD-3 study, the 5-year survival rate of lung cancer patients in Finland has not improved during the twenty-first century. In the present study, we evaluated the...
4.
Leskela R, Peltonen E, Haavisto I, Herse F, Korhonen S, Nolvi K, et al.
Acta Oncol
. 2022 Apr;
61(5):641-648.
PMID: 35411839
Introduction: Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality in the Western world. However, emerging treatment options and more patients directed to active treatments might improve...
5.
Iivanainen S, Ahvonen J, Aija Knuuttila , Tiainen S, Koivunen J
ESMO Open
. 2019 Sep;
4(4):e000531.
PMID: 31555483
Background: Anti-PD-(L)1 agents are standard of care treatments in various cancers but predictive factors for therapy selection are limited. We hypothesised that markers of systemic inflammation would predict adverse outcomes...